Quantinno Capital Management LP Buys 298,342 Shares of Healthpeak Properties, Inc. $DOC

Quantinno Capital Management LP increased its position in Healthpeak Properties, Inc. (NYSE:DOC) by 58.8% in the 1st quarter, HoldingsChannel reports. The fund owned 805,500 shares of the real estate investment trust’s stock after buying an additional 298,342 shares during the quarter. Quantinno Capital Management LP’s holdings in Healthpeak Properties were worth $13,234,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also added to or reduced their stakes in DOC. Fiduciary Trust Co boosted its position in shares of Healthpeak Properties by 4.9% in the third quarter. Fiduciary Trust Co now owns 13,807 shares of the real estate investment trust’s stock worth $264,000 after purchasing an additional 644 shares during the period. Patton Fund Management Inc. raised its position in shares of Healthpeak Properties by 5.2% during the 4th quarter. Patton Fund Management Inc. now owns 13,002 shares of the real estate investment trust’s stock valued at $209,000 after purchasing an additional 648 shares during the period. Quadrant Capital Group LLC lifted its stake in shares of Healthpeak Properties by 1.9% during the 3rd quarter. Quadrant Capital Group LLC now owns 37,650 shares of the real estate investment trust’s stock valued at $721,000 after buying an additional 718 shares in the last quarter. Quantum Portfolio Management LLC lifted its stake in shares of Healthpeak Properties by 2.5% during the 1st quarter. Quantum Portfolio Management LLC now owns 29,372 shares of the real estate investment trust’s stock valued at $483,000 after buying an additional 728 shares in the last quarter. Finally, Intrua Financial LLC boosted its holdings in Healthpeak Properties by 1.1% in the 1st quarter. Intrua Financial LLC now owns 66,702 shares of the real estate investment trust’s stock worth $1,096,000 after buying an additional 744 shares during the period. Hedge funds and other institutional investors own 93.57% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on DOC. UBS Group increased their price target on Healthpeak Properties from $19.00 to $21.50 and gave the stock a “neutral” rating in a research note on Wednesday, July 8th. JPMorgan Chase & Co. upped their price objective on Healthpeak Properties from $18.00 to $21.00 and gave the stock a “neutral” rating in a research note on Wednesday, June 24th. Morgan Stanley reissued an “equal weight” rating and set a $22.00 target price (up from $20.00) on shares of Healthpeak Properties in a research note on Thursday, June 11th. Citigroup boosted their price target on Healthpeak Properties from $17.50 to $20.00 and gave the stock a “neutral” rating in a report on Tuesday, May 12th. Finally, BMO Capital Markets upped their price target on Healthpeak Properties from $20.00 to $24.00 and gave the stock an “outperform” rating in a research note on Monday, June 15th. Four analysts have rated the stock with a Buy rating and fifteen have assigned a Hold rating to the company. According to MarketBeat, the company has a consensus rating of “Hold” and a consensus target price of $20.62.

Insider Activity

In other news, insider Scott R. Bohn sold 10,989 shares of the company’s stock in a transaction dated Tuesday, May 12th. The shares were sold at an average price of $19.45, for a total transaction of $213,736.05. Following the sale, the insider directly owned 7,636 shares in the company, valued at approximately $148,520.20. This represents a 59.00% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 0.23% of the company’s stock.

Healthpeak Properties Stock Performance

NYSE:DOC opened at $21.68 on Tuesday. The company has a market cap of $14.95 billion, a price-to-earnings ratio of 67.77, a PEG ratio of 3.39 and a beta of 1.02. Healthpeak Properties, Inc. has a 1 year low of $15.70 and a 1 year high of $22.95. The stock’s 50 day simple moving average is $21.05 and its two-hundred day simple moving average is $18.70. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.96 and a quick ratio of 2.96.

Healthpeak Properties (NYSE:DOC) last announced its quarterly earnings results on Tuesday, May 5th. The real estate investment trust reported $0.45 earnings per share for the quarter, topping the consensus estimate of $0.43 by $0.02. The company had revenue of $752.95 million for the quarter, compared to analysts’ expectations of $694.59 million. Healthpeak Properties had a net margin of 7.73% and a return on equity of 2.61%. Healthpeak Properties’s quarterly revenue was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.46 earnings per share. As a group, equities analysts anticipate that Healthpeak Properties, Inc. will post 1.75 earnings per share for the current fiscal year.

Healthpeak Properties Dividend Announcement

The firm also recently announced a monthly dividend, which will be paid on Friday, September 25th. Stockholders of record on Monday, September 14th will be issued a $0.1017 dividend. The ex-dividend date is Monday, September 14th. This represents a c) dividend on an annualized basis and a dividend yield of 5.6%. Healthpeak Properties’s payout ratio is 381.25%.

Healthpeak Properties Company Profile

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.